EGF-liposomes promote efficient EGFR targeting in xenograft colocarcinoma model
Abstract
AIM: Development of EGF-liposomes (LP-EGF) for selective molecules delivery in tumors expressing EGFR. MATERIAL & METHODS: In vitro cellular interaction of EGF-LP and nontargeted liposomes (LP-N) was assayed at 37 and 4 °C in cells expressing different EGFR levels. Receptor-mediated uptake was investigated by competition with a monoclonal antibody anti-EGFR. Selective intracellular drug delivery and efficacy was tested by oxaliplatin encapsulation. In vivo biodistribution of LP-N and LP-EGF was done in xenograft model. RESULTS: LP-EGF was internalized by an active and selective mechanism through EGFR without receptor activation. Oxaliplatin LP-EGF decreased IC50 between 48 and 13% in cell EGFR+. LP-EGF was accumulated in tumor over 72 h postdosing, while LP-N in spleen. CONCLUSION: LP-EGF represents an attractive nanosystem for cancer therapy or diagnosis.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
EGF-liposome conjugates remarkably reduced IC50 of oxaliplatin in colorectal cancer cells overexpressing EGFR, but not in EGFR-negative colorectal cancer cells.
“EGF-liposome conjugates remarkably reduced the IC50 value of oxaliplatin in colorectal cancer cells which overexpressed ERFR, though not in the EGFR-negative colorectal cancer cells [51].”
From Approaches to Improve EPR-Based Drug Delivery for Cancer Therapy and Diagnosis (2023) · cites this paper as [51]
Enhanced EPR effect and therapeutic efficiency may be achieved by targeting EGFR in TME.
“This study indicated that the enhanced EPR effect and therapeutic efficiency may be achieved by targeting EGFR in TME.”
From Approaches to Improve EPR-Based Drug Delivery for Cancer Therapy and Diagnosis (2023) · cites this paper as [51]
Cites
Rouser, G., Fleischer, S., & Yamamoto, A. (1970) · Lipids · doi:10.1007/bf02531316 · Cited by 3,280 · see citing works
Maeda, H. (2001) · Advances in Enzyme Regulation · doi:10.1016/s0065-2571(00)00013-3 · Cited by 2,495 · see citing works
Ligand-targeted therapeutics in anticancer therapy
Allen, T. M. (2002) · Nature reviews. Cancer · doi:10.1038/nrc903 · Cited by 1,648 · see citing works
Targeting the EGFR signaling pathway in cancer therapy
Seshacharyulu, P., Ponnusamy, M. P., Haridas, D., Jain, M., Ganti, A. K., & Batra, S. K. (2012) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2011.648617 · Cited by 913 · see citing works
Bhirde, A. A., Patel, V., Gavard, J., Zhang, G., Sousa, A. A., Masedunskas, A., Leapman, R. D., Weigert, R., Gutkind, J. S., & Rusling, J. F. (2009) · ACS Nano · doi:10.1021/nn800551s · Cited by 852 · see citing works
Targeted pharmaceutical nanocarriers for cancer therapy and imaging
Torchilin, V. P. (2007) · The AAPS Journal · doi:10.1208/aapsj0902015 · Cited by 758 · see citing works
Current Trends in The Use of Liposomes for Tumor Targeting
Deshpande, P. P., Biswas, S., & Torchilin, V. P. (2013) · Nanomedicine · doi:10.2217/nnm.13.118 · Cited by 663 · see citing works
Epidermal growth factor receptor targeting in cancer: a review of trends and strategies
Yewale, C., Baradia, D., Vhora, I., Patil, S., & Misra, A. (2013) · Biomaterials · doi:10.1016/j.biomaterials.2013.07.100 · Cited by 533 · see citing works
PEGylation of Proteins and Liposomes: a Powerful and Flexible Strategy to Improve the Drug Delivery
Milla, P., Dosio, F., & Cattel, L. (2011) · Current Drug Metabolism · doi:10.2174/138920012798356934 · Cited by 427 · see citing works
Ligand-targeted particulate nanomedicines undergoing clinical evaluation: Current status
van der Meel, R., Vehmeijer, L. J. C., Kok, R. J., Storm, G., & van Gaal, E. V. B. (2013) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2013.08.012 · Cited by 398 · see citing works
Lee, H., Fonge, H., Hoang, B., Reilly, R. M., & Allen, C. (2010) · Molecular Pharmaceutics · doi:10.1021/mp100038h · Cited by 349 · see citing works
Shimizu, M., Deguchi, A., Lim, J. T. E., et al. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-2014 · Cited by 348 · see citing works
Anti-epidermal growth factor receptor monoclonal antibodies in cancer therapy
Martinelli, E., Palma, R. D., Orditura, M., Vita, F. D., & Ciardiello, F. (2009) · Clinical & Experimental Immunology · doi:10.1111/j.1365-2249.2009.03992.x · Cited by 334 · see citing works
The EGF receptor is required for efficient liver regeneration
Natarajan, A., Wagner, B., & Sibilia, M. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0704126104 · Cited by 320 · see citing works
Hansen, C. B., Kao, G. Y., Moase, E. H., Zalipsky, S., & Allen, T. M. (1995) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/0005-2736(95)00138-s · Cited by 309 · see citing works
Newman, M. S., Colbern, G. T., Working, P. K., Engbers, C. M., & Amantea, M. (1999) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s002800050855 · Cited by 275 · see citing works
Weng, K. C., Noble, C. O., Papahadjopoulos‐Sternberg, B., Chen, F. F., Drummond, D. C., Kirpotin, D. B., Wang, D., Hom, Y. K., Hann, B. C., & Park, J. W. (2008) · Nano Letters · doi:10.1021/nl801488u · Cited by 274 · see citing works
Membrane‐anchored growth factors, the epidermal growth factor family: Beyond receptor ligands
Higashiyama, S., Iwabuki, H., Morimoto, C., Hieda, M., Inoue, H., & Matsushita, N. (2008) · Cancer Science · doi:10.1111/j.1349-7006.2007.00676.x · Cited by 213 · see citing works
Peptide ligand-mediated liposome distribution and targeting to EGFR expressing tumor in vivo
Song, S., Liu, D., Peng, J., Sun, Y., Li, Z., Gu, J., & Xu, Y. (2008) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2008.07.012 · Cited by 180 · see citing works
Assessment of Cell Proliferation with Resazurin-Based Fluorescent Dye
Czekanska, E. M. (2011) · Methods in molecular biology · doi:10.1007/978-1-61779-108-6_5 · Cited by 169 · see citing works
Zalba, S., Contreras-Sandoval, A. M., Haeri, A., ten Hagen, T. L. M., Navarro-Blasco, Í., Koning, G. A., & Garrido, M. J. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.05.271 · Cited by 120 · see citing works
Self-citationDiverse expression of ErbB receptor proteins during rat liver development and regeneration
Carver, R. S., Stevenson, M. C., Scheving, L. A., & Russell, W. E. (2002) · Gastroenterology · doi:10.1053/gast.2002.37060 · Cited by 111 · see citing works
Lee, P., Chiou, Y.-C., Wong, J., et al. (2013) · Biomaterials · doi:10.1016/j.biomaterials.2013.07.067 · Cited by 107 · see citing works
Sikorski, A. F., Toporkiewicz, M., Meissner, J. M., Matusewicz, L., & Czogalla, A. (2015) · International Journal of Nanomedicine · doi:10.2147/ijn.s74514 · Cited by 104 · see citing works
Liposomes, a promising strategy for clinical application of platinum derivatives
Zalba, S., & Garrido, M. J. (2013) · Expert Opinion on Drug Delivery · doi:10.1517/17425247.2013.778240 · Cited by 66 · see citing works
Self-citationEpidermal Growth Factor Receptor Inhibitors: Coming of Age
Mahipal, A., Kothari, N., & Gupta, S. (2014) · Cancer Control · doi:10.1177/107327481402100111 · Cited by 66 · see citing works
Wild, R. A., Fager, K., Flefleh, C., Kan, D., Inigo, I. V., Castaneda, S., Luo, F. R., Camuso, A., McGlinchey, K., & Rose, W. C. (2006) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-05-0259 · Cited by 62 · see citing works
Dendrimer-triglycine-EGF nanoparticles for tumor imaging and targeted nucleic acid and drug delivery
Yuan, Q., Lee, E., Yeudall, W. A., et al. (2010) · Oral Oncology · doi:10.1016/j.oraloncology.2010.07.001 · Cited by 57 · see citing works
Beuttler, J., Rothdiener, M., Müller, D., et al. (2009) · Bioconjugate Chemistry · doi:10.1021/bc900061v · Cited by 53 · see citing works
Mamot, C., Ritschard, R., WICKI, A. N., Küng, W., Schuller, J. C., Herrmann, R., & Rochlitz, C. F. (2012) · Journal of drug targeting · doi:10.3109/1061186x.2012.680960 · Cited by 52 · see citing works
Zalba, S., Navarro-Blasco, Í., Trocóniz, I. F., de Ilarduya, C. T., & Garrido, M. J. (2012) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2012.02.007 · Cited by 49 · see citing works
Self-citationDevelopment of targeted therapy with paclitaxel incorporated into EGF-conjugated nanoparticles.
Shimada, T., Ueda, M., Jinno, H., Chiba, N., Wada, M., Watanabe, J., Ishihara, K., & Kitagawa, Y. (2009) · PubMed · Cited by 43 · see citing works
Kalimutho, M., Minutolo, A., Grelli, S., et al. (2010) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-010-1428-4 · Cited by 33 · see citing works
Efficient Gene Delivery by EGF-LipoplexesIn VitroandIn Vivo
Buñuales, M., Düzgüneş, N., Zalba, S., et al. (2010) · Nanomedicine · doi:10.2217/nnm.10.100 · Cited by 29 · see citing works
Self-citationZhang, X., Yin, Y., Liu, -, M., Wang, & Hao (2012) · International Journal of Nanomedicine · doi:10.2147/ijn.s30671 · Cited by 27 · see citing works
Skvortsov, S., Sarg, B., Lindner, H. H., Lukas, P. H., Hilbe, W., Zwierzina, H., & Skvortsova, I. (2008) · PROTEOMICS - CLINICAL APPLICATIONS · doi:10.1002/prca.200780034 · Cited by 21 · see citing works
Biological Barriers and Current Strategies for Modifying Nanoparticle Bioavailability
Prantner, A. M., & Scholler, N. (2014) · Journal of Nanoscience and Nanotechnology · doi:10.1166/jnn.2014.8899 · Cited by 19 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Approaches to Improve EPR-Based Drug Delivery for Cancer Therapy and Diagnosis
Subhan, M. A., Parveen, F., Filipczak, N., Yalamarty, S. S. K., & Torchilin, V. P. (2023) · Journal of Personalized Medicine · doi:10.3390/jpm13030389 · Cited by 98 · see citing works
“EGF-liposome conjugates remarkably reduced the IC50 value of oxaliplatin in colorectal cancer cells which overexpressed ERFR, though not in the EGFR-negative colorectal cancer cells [51].”
Background
- Authors
- Zalba, S., Contreras, A. M., Merino, M., Navarro, I., de Ilarduya, C. T., Trocóniz, I. F., Koning, G., & Garrido, M. J.
- Affiliations
- Erasmus MC (NL)
- Department of Pharmacy & Pharmaceutical Technology, School of Pharmacy, University of Navarra, Pamplona, Spain
- Universidad de Navarra (ES)
- Department of Chemistry & Edaphology, University of Navarra, Pamplona, Spain
- Venue
- Nanomedicine
- Publisher
- Informa UK Limited
- Published
- 2016-02-19
- Volume
- 11
- Issue
- 5
- Pages
- 465-477
- ISSN
- 1743-5889 (ISSN-L)
- 1748-6963
- OpenAlex
- W2278535141
- Cited by
- 26
- References
- 37
- Citations by year
- 2025: 2 · 2024: 2 · 2023: 3 · 2022: 5 · 2021: 3 · 2020: 4 · 2019: 4 · 2018: 1 · 2016: 2
- FWCI
- 0.95
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Nanomedicine (publishedVersion)
- PubMed (publishedVersion)
- EUR Research Repository (Erasmus University Rotterdam) (submittedVersion)
- Topics
- Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Health Sciences › Medicine › Oncology › Drug Transport and Resistance Mechanisms
- Keywords
- EGFR targeting, receptor-mediated endocytosis, targeted drug delivery, tumor xenografts, tissue distribution, colorectal cancer, liposomal drug delivery
- MeSH terms
- Oxaliplatin, Animals, Epidermal Growth Factor, Humans, Liposomes, Organoplatinum Compounds, Colorectal Neoplasms, Drug Delivery Systems, Xenograft Model Antitumor Assays, Cell Line, Tumor, Mice, Molecular Targeted Therapy, ErbB Receptors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
